EAI045 is a selective allosteric inhibitor that potently targets drug-resistant EGFR mutants while sparing the wild-type receptor. It is a valuable chemical probe for studying resistance mechanisms in non-small cell lung cancer (NSCLC) and has demonstrated efficacy in both cellular assays and in vivo models.